LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50
participants with recurrent glioblastoma which are schedule for resection. In the lead-in
cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial.
Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of
their tumor. If positive PK results are demonstrated in ≥50% of Phase 0 participants and at
least 5 participants are enrolled into Phase 2, up to approximately 40 additional
participants will be enrolled in the dose expansion cohort in order to achieve a total of 25
participants enrolled into Phase 2 (lead-in cohort + dose expansion).
Phase:
Early Phase 1
Details
Lead Sponsor:
Nader Sanai
Collaborators:
Barrow Neurological Institute Eli Lilly and Company Ivy Brain Tumor Center